Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disorders

Translational Psychiatry

Volumn 4, Issue , 2014, Pages

  Ray, M T ^a,b   Weickert, C Shannon ^c,d,e   Webster, M J ^a  

^a Stanley Laboratory of Brain Research   (United States)

^b Trinity Washington University   (United States)

^c SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^d NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; MESSENGER RNA; NEUROTROPHIN; FLUPHENAZINE; MEMBRANE PROTEIN; PROTEIN TYROSINE KINASE; TROPOMYOSIN-RELATED KINASE-B, HUMAN;

ADULT; ANTERIOR CINGULATE; ARTICLE; BIPOLAR DISORDER; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSIS RELATED GROUP; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FRONTAL CORTEX; HUMAN; IN SITU HYBRIDIZATION; INFERIOR TEMPORAL GYRUS; MAJOR DEPRESSION; MALE; MOOD DISORDER; NEOCORTEX; NERVE CELL PLASTICITY; ORBITAL CORTEX; PREFRONTAL CORTEX; PROTEIN EXPRESSION; SCHIZOPHRENIA; SUPERIOR TEMPORAL GYRUS; ALCOHOL ABUSE; COHORT ANALYSIS; COMPARATIVE STUDY; CORTEX LAYER VI; DORSOLATERAL PREFRONTAL CORTEX; LEFT HEMISPHERE; MEDICAL HISTORY; PH; TIME OF DEATH; CINGULATE GYRUS; FRONTAL LOBE; METABOLISM; MIDDLE AGED; PATHOLOGY; TEMPORAL LOBE;

ADULT; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER, MAJOR; FEMALE; FRONTAL LOBE; GYRUS CINGULI; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROTEIN-TYROSINE KINASES; RNA, MESSENGER; SCHIZOPHRENIA; TEMPORAL LOBE;

EID: 84901235787     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.26     Document Type: Article

References (80)

1. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999; 122: 593-624.
2. Hirsch SR, Weinberger DR. Schizophrenia. Blackwell Science: Oxford; Cambridge, MA, USA, 1995.
3. Taylor MA. Are schizophrenia and affective disorder related A selective literature review. Am J Psychiatry 1992; 149: 22-32.
4. Taylor MA, Amir N. Are schizophrenia and affective disorder related The problem of schizoaffective disorder and the discrimination of the psychoses by signs and symptoms. Comp Psychiatry 1994; 35: 420-429.
5. Bora E, Fornito A, Radua J, Walterfang M, Seal M, Wood SJ et al. Neuroanatomical abnormalities in schizophrenia: a multimodal voxelwise meta-analysis and metaregression analysis. Schizophr Res 2011; 127: 46-57.
6. Bora E, Fornito A, Yucel M, Pantelis C. The effects of gender on grey matter abnormalities in major psychosis: a comprehensive voxelwise meta-analysis of schizophrenia and bipolar disorder. Psychol Med 2012; 42: 295-307.
7. Bora E, Harrison BJ, Davey CG, Yucel M, Pantelis C. Meta-analysis of volumetric abnormalities in cortico-striatal-pallidal-thalamic circuits in major depressive disorder. Psychol Med 2012; 42: 671-681.
8. Thompson M, Weickert CS, Wyatt E, Webster MJ. Decreased glutamic acid decarboxylase (67) mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders. J Psychiatr Res 2009; 43: 970-977.
9. Lu B. BDNF and activity-dependent synaptic modulation. Learn Mem 2003; 10: 86-98.
10. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003; 8: 592-610.
11. Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 2005; 25: 372-383.
12. Pillai A. Decreased expression of Sprouty2 in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder: a correlation with BDNF expression. PLoS One 2008; 3: e1784.
13. Issa G, Wilson C, Terry AV, Pillai A. An inverse relationship between cortisol and BDNF levels in schizophrenia: Data from human postmortem and animal studies. Neurobiol Dis 2010; 39: 327-333.
14. Wong J, Hyde TM, Cassano HL, Deep-Soboslay A, Kleinman JE, Weickert CS. Promoter specific alterations of BDNF mRNA in schizophrenia. Neuroscience 2010; 169: 1071-1084.
15. Kim H-W, Rapoport SI, Rao JS. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol Dis 2010; 37: 596-603.
16. Qi X-R, Zhao J, Liu J, Fang H, Swaab DF, Zhou J-N. Abnormal retinoid and TrkB signaling in the prefrontal cortex in mood disorders. Cereb Cortex 2013,doi:10.1093/cercor/bht203.
17. Thompson Ray M, Weickert CS, Wyatt E, Webster MJ. Decreased BDNF, trk-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci 2011; 36: 195-203.
18. Dunham JS, Deakin JFW, Miyajima F, Payton A, Toro CT. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. J Psychiatr Res 2009; 43: 1175-1184.
19. Weickert CS, Ligons DL, Romanczyk T, Ungaro G, Hyde TM, Herman MM et al. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2005; 10: 637-650.
20. Wong J, Rothmond DA, Webster MJ, Weickert CS. Increases in two truncated TrkB isoforms in the prefrontal cortex of people with schizophrenia. Schizophr Bull 2013; 39: 130-140.
21. Tripp A, Hyunjung O, Guilloux J-P, Martinowich K, Lewis DA, Sibille E. Brainderived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. Am J Psychiatry 2012; 169: 1194-1202.
22. Soontornniyomkij B, Everall IP, Chana G, Tsuang MT, Achim CL, Soontornniyomkij V. Tyrosine kinase B protein expression is reduced in the cerebellum of patients with bipolar disorder. J Affect Disord 2011; 133: 646-654.
23. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatr 2003; 60: 804-815.
24. Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R. Neurotrophin levels in postmortem brains of suicide victims and the antemortem diagnosis and psychotropic drugs. Mol Brain Res 2005; 136: 29-37.
25. Pandey GN, Ren X, Rizavi HS, Conley RR, Roberts RC, Dwivedi Y. Brain-derived neurotrophic factor and tyrosine B receptor signaling in post-mortem brain of teenage suicide victims. Int J Neuropsychopharmacol 2008; 11: 1047-1061.
26. Banerjee P, Ghosh AK, Ghosh B, Bhattacharyya S, Mondal AC. Decreased mRNA and protein expression of BDNF, NGF, and their receptor in the hippocampus from suicide: an analysis in human postmortem brain. Clin Med Insights Pathol 2013; 6: 1-11.
27. Rajkowska G, Goldman-Rakic PS. Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. remapping of areas 9 and 46 using quantitative criteria. Cereb Cortex 1995; 5: 307-322.
28. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999; 45: 1085-1098.
29. Vogt BA, Nimchinsky EA, Vogt LJ, Hof PR. Human cingulate cortex: surface features, flat maps, and cytoarchitecture. J Comp Neurol 1995; 359: 490-506.
30. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The Stanley Foundation brain collection and neuropathology consortium. Schizophr Res 2000; 44: 151-155.
31. Romanczyk TB, Weickert CS, Webster MJ, Herman MM, Akil M, Kleinman JE. Alterations in trkB mRNA in the human prefrontal cortex throughout the lifespan. Eur J Neurosci 2002; 15: 269-280.
32. Whitfield HJ Jr, Brady LS, Smith MA, Mamalaki E, Fox RJ, Herkenham M. Optimization of cRNA probe in situ hybridization methodology for localization of glucocorticoid receptor mRNA in rat brain: a detailed protocol. Cell Mol Neurobiol 1990; 10: 145-157.
33. Chen B, Dowlatshahi D, MacQueen MG, Wang J-F, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260-265.
34. Guilloux J-P, Douillard-Guilloux G, Kota R, Wang X, Gardier AM, Martinowich K et al. Molecular evidence for BDNF-and GABA-related dysfunctions in the amygdala of female subjects with depression. Mol Psychiatry 2012; 17: 1130-1142.
35. Mizuno K, Carnahan J, Nawa H. Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev Biol 1994; 165: 243-256.
36. Ventimiglia R, Mather PE, Jones PE, Lindsay RM. The neurotrophins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur J Neurosci 1995; 7: 213-222.
37. Altar CA, DiStefano PS. Neurotrophin trafficking by anterograde transport. Trends Neurosci 1998; 21: 433-437.
38. Ivkovic S, Ehrlich ME. Expression of the striatal DARPP-32/ARPP-21 phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro. J Neurosci 1999; 19: 5409-5419.
39. Cotter D, MacKay D, Chana G, Beasley C, Landau S, Everal IP. Reduced neuronal size and glial cell density in area of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 2002; 12: 386-394.
40. Cotter D, Hudson L, Landau S. Evidence for orbitofrontal pathology in bipolar disorder and major depression, but not in schizophrenia. Bipolar Dis 2005; 7: 358-369.
41. Chana G, Landau S, Beasley C, Everall IP, Cotter D. Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder and schizophrenia: evidence for decreased neuronal somal size and increased neuronal density. Biol Psychiatry 2003; 53: 1086-1098.
42. Cotter D, MacKay D, Landau S, Kerwin R, Everal IP. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001; 58: 545-553.
43. Law AJ, Harrison PJ. The distribution and morphology of prefrontal cortex pyramidal neurons identified using anti-neurofilament antibodies SMI32, N200 and FNP7. Normative data and a comparison in subjects with schizophrenia, bipolar disorder or major depression. J Psychiatr Res 2003; 37: 487-499.
44. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Ann Rev Neurosci 2001; 24: 677-736.
45. Gorski JA, Zeiler SR, Tamowski S, Jones KR. Brain derived neurotrophic factor is required for the maintenance of cortical dendrites. J Neurosci 2003; 23: 6856-6865.
46. Lu B, Martinowich K. Cell biology of BDNF and its relevance to schizophrenia. Novartis Found Symp 2008; 289: 119-195.
47. Jourdi H, Kabbaj M. Acute BDNF treatment upregulates GluR1-SAP97 and GluR2-GRIP1 interactions: Implications for sustained AMPA receptor expression. PLoS One 2013; 8: e57124.
48. Eastwood SL, Harrison PJ. Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders: a review and a western blot study of synaptophysin, GAP-43 and the complexins. Brain Res Bull 2001; 55: 569-578.
49. Beasley CL, Honer WG, Bergmann K, Falkai P, Lutjohann D, Bayer TA. Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Dis 2005; 7: 449-455.
50. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D. Proteomic analysis of the anterior cingulate cortex in schizophrenia, bipolar disorder and major depressive disorder: evidence for disease-associated changes. Proteomics 2006; 6: 3414-3425.
51. Ryan MM, Lockstone HE, Huffaker SJ, Wayland MT, Webster MJ, Bahn S. Gene expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes. Mol Psychiatry 2006; 11: 965-978.
52. Porton B, Wetsel WC. Reduction of synapsin III in the prefrontal cortex of individuals with schizophrenia. Schizophr Res 2007; 94: 366-370.
53. Pennington K, Dicker P, Dunn MJ, Cotter DR. Proteomic analysis reveals protein changes within layer 2 of the insular cortex in schizophrenia. Proteomics 2008; 8: 5097-5107.
54. Hattori K, Tanaka H, Wakabayashi C, Yamamoto N, Uchiyama H, Teraishi Tet al. Expression of Ca(2+)-dependent activator protein for secretion 2 is increased in the brains of schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1738-1743.
55. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000; 28: 53-67.
56. Kolluri N, Sun Z, Sampson AR, Lewis DA. Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 2005; 162: 1200-1202.
57. Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariante CM et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 2008; 13: 1102-1117.
58. Behan AT, Byrne C, Dunn MJ, Cagney G, Cotter DR. Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. Mol Psychiatry 2009; 141: 601-613.
59. Wong J, Webster MJ, Cassano H, Weickert CS. Changes in alternative brainderived neurotrophic factor transcript expression in the developing human prefrontal cortex. Eur J Neurosci 2009; 29: 1311-1322.
60. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002; 328: 261-264.
61. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical syudies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmol 2008; 11: 1169-1180.
62. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression and antidepressant medications: Meta-analyses and implications. Biol Psychiatry 2008; 64: 527-532.
63. Bocchio-Chiavetto L, Bagnardi V, Zanardin R, Molteni R, Nielsen MG, Placentino A et al. Serum and plasma BDNF levels in major depression: A replication study and meta-analysis. World J Biol Psychiatry 2011; 11: 763-773.
64. Fernandes BS, Gama CS, Cereser KM, Yatham LN, Fries GR, Colpo G et al. Brainderived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: A systematic review and meta-regression analysis. J Psychiatr Res 2011; 45: 995-1004.
65. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 2011; 16: 960-972.
66. Linden AM, Vaisanen J, Lakso M, Nawa H, Wong G, Castren E. Expression of neurotrophins BDNF and NT-3 and their receptors in rat brain after administration of antipsychotic and psychotrophic agents. J Mol Neurosci 2000; 14: 27-37.
67. Lipska BK, Khaing ZZ, Weickert CS, Weinberger DR. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal neonatal ventral hippocampal damage and antipsychotic drugs. Eur J Neurosci 2001; 14: 135-144.
68. Chlan-Fourney J, Ashe P, Nylen K, Juorio AV, Li X-M. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res 2002; 954: 11-20.
69. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li X-M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003; 71: 127-131.
70. Angelucci F, Aloe L, Iannitelli A, Gruber SHM, Mathe AA. Effects of chronic olanzapine on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur Neuropsychopharmacol 2005; 15: 311-317
71. Pillai A, Terry AV, Mahadik SP. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res 2006; 82: 95-106.
72. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116-1127.
73. Bayer TA, Schramm M, Feldmann N, Knable MB, Falkai P. Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24: 881-888.
74. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-7547.
75. Russo-Neustadt A, Beard RC, Cotman CW. Exercise, antidepressant medications and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 1999; 21: 679-682.
76. Altar CA, Whitehead RE, Chen R, Wortwein G, Madsen TM. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 2003; 54: 703-709.
77. Rogoz Z, Skuza G, Leutko B. Repeated treatment with mirtazapine induces brainderived neurotrophic factor gene expression in rats. J Physiol Pharmacol 2005; 56: 661-671.
78. Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, Lucki I. Differential regulation of central BDNF protein levels by antidepressant and nonantidepressant drug treatments. Brain Res 2008; 1211: 37-43.
79. Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA et al. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington?s disease mouse model. Exp Neurol 2008; 210: 154-163.
80. Kavalali ET, Monteggia LM. Synaptic machanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry 2012; 169: 1150-1156.